David-Alexandre C. Gros - 31 Jul 2026 Form 4 Insider Report for Eledon Pharmaceuticals, Inc. (ELDN)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: ELDN
Reported as of: 31 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Aug 2026, 17:22:36 UTC
Prior SEC filing: 13 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Paul Little, as attorney-in-fact for David-Alexandre C. Gros, M.D.

Key filing fact

David-Alexandre C. Gros filed Form 4 for Eledon Pharmaceuticals, Inc. (ELDN) on 04 Aug 2026.

Key facts

This page summarizes David-Alexandre C. Gros's Form 4 filing for Eledon Pharmaceuticals, Inc. (ELDN).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 04 Aug 2026, 17:22.

Change

Previous filing in this sequence was filed on 13 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001644489 Primary reporting owner

Gros David-Alexandre C

Relationship: Chief Executive Officer, Director
Address: C/O ELEDON PHARMACEUTICALS, INC., 19800 MACARTHUR BLVD STE. 250, IRVINE
Signature: /s/ Paul Little, as attorney-in-fact for David-Alexandre C. Gros, M.D.
Signature date: 04 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ELDN transaction

Common Stock

Award

Transaction value
Shares: +354,454
Change %: +3938%
Price: $0.000000^*
Shares after: 363,454
Date: 31 Jul 2026
Ownership: Direct
Footnotes: F1

ELDN transaction

Common Stock

Tax liability

Transaction value
Shares: -194,791
Change %: -54%
Price: $3.38^*
Shares after: 168,663
Date: 31 Jul 2026
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents shares issuable on settlement of a retention bonus award granted to the Reporting Person. The retention bonus agreement was entered into on April 27, 2023.

Footnote F2

Represents shares withheld to pay tax withholding obligations due on the date of settlement.